Breaks Categories: News

FridayAug 07, 2020 10:40 am

BioMedNewsBreaks – DarioHealth (NASDAQ: DRIO) Announces Plans to Release Q2 Financials, Provide Company Update

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, will release its second-quarter earnings on June 30, 2020, as well as host a 9 a.m. ET conference call and webcast on the same day. Hosted by CEO Erez Raphael, president and North America general manager Rick Anderson, and CFO Zvi Ben-David, the call will include a business update as well as an earnings discussion. Interested parties are invited to participate by dialing 1-844-369-8770 (in the United States) or 1-862-298-0840 (internationally) or visiting http://ibn.fm/wQKu5. Those who are participating are asked to dial in or log in 10 minutes prior to the start…

Continue Reading

WednesdayAug 05, 2020 1:33 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Rides Deal Wave to Stock Bump

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is riding a wave that pushed its stock up 20% with no DRIO-related news. An article published to MarketWatch today titled, “UPDATE: Teladoc and Livongo Health to merge in deal valued at $18.5 billion,” covers a move amid a trend toward virtual healthcare that places DRIO, a provider of digital health solutions, in the right place at the right time. The article reads, “Teladoc Health Inc. (NYSE: TDOC) and Livongo Health Inc. (NASDAQ: LVGO) said Wednesday they have agreed to merge in a deal valued at $18.5 billion to…

Continue Reading

FridayJul 31, 2020 1:53 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Closes $28.6M Private Placement to Fund Long-Term Operating Plan

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has completed a private placement transaction resulting in aggregate gross proceeds of an estimated $28.6 million. After deducting placement agent fees and other offering expenses, capital from the transaction, along with existing balance sheet cash, will be used to fund DRIO’s long-term strategic operating plan. "We are pleased to have the confidence of our largest shareholder and several new highly regarded healthcare investors as we expand our commercial to manage existing and anticipated near-term agreements with health care payers," said Dario CEO Erez Raphael, chief executive officer of Dario. "The…

Continue Reading

FridayJul 31, 2020 11:04 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO Again Featured on ‘Big Biz Show,’ to Present at Proactive’s One2One Virtual Investor Forum

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, on Thursday announced participation by its chairman and CEO, Rodney Varner, in a second-round live interview on the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show. A replay of the interview is available for viewing on the company’s website. In addition, Genprex today announced that it will present at the Proactive Investors One2One Virtual Event at 1:40 p.m. ET on August 4, 2020. Varner will deliver a company overview, provide updates on its product pipeline, including its lead…

Continue Reading

FridayJul 24, 2020 12:55 pm

BioMedNewsBreaks – AIkido Pharma Inc. (NASDAQ: AIKI) Provides Update on Computational Approaches to Identify Virus Treatments

AIkido Pharma (NASDAQ: AIKI) recently provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. According to the update, AIkido previously announced an executed a master license agreement with the University of Maryland, Baltimore ("UMB"), covering certain antiviral compounds discovered by UMB. Recently, UMB researchers have identified a human protein complex (called the “SKI” complex) that is important for replication of several viruses including Influenza, COVID-19, SARS1, MERS, SARS2, Ebola and Marburg. Utilizing information gleaned from initial research and the power of a computer modeling approach called SILCS, combined with machine learning tools, the researchers…

Continue Reading

TuesdayJul 21, 2020 11:16 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $2.59M NIH Research Grant to Lead Researcher Behind Its Diabetes Gene Therapy

Genprex (NASDAQ: GNPX), today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the company’s potentially curative diabetes gene therapy, was awarded a grant of $2.59 million from the National Institutes of Health (“NIH”) National Institute of Diabetes and Digestive and Kidney Diseases. According to the update, the grant will assist Dr. Gittes’ development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes. “We are excited to receive this funding to support…

Continue Reading

MondayJul 20, 2020 11:17 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters Strategic Agreement to Offer World-Class RPM Solution to HCPs Across the UK and Ireland

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced its entry into a new strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to Healthcare Professionals (“HCPs”) across the United Kingdom and Ireland. According to the update, Dario's turn-key RPM solution integrates the company's existing open platform, application technology, and the DarioEngage coaching platform, to allow Healthcare Professionals to monitor their patients remotely. "We are very excited about this partnership between DarioHealth and Williams Medical, as this aligns with our international growth initiative by offering our world-class RPM…

Continue Reading

TuesdayJul 14, 2020 11:03 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Appointments

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors, effective immediately. According to the update, joining the board as independent directors are: Dr. Nancy Chung-Welch, Ph.D., Charles L. Nuzum, CPA and Greg St. Clair. “These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,”…

Continue Reading

ThursdayJul 09, 2020 1:07 pm

BioMedNewsBreaks – CRISPR Therapeutics (NASDAQ: CRSP) Secures $517.5M in Underwritten Public Offering

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, has closed an underwritten public offering of 7,392,857 common shares, including 964,285 additional shares per the full exercise of the over-allotment option granted to the underwriters. CRISPR Therapeutics secured approximately $517.5 million in gross proceeds, with each of the shares sold at the public offering price of $70.00. ROTH Capital Partners acted as co-manager for the offering. For more information, visit www.CRISPRtx.com. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its…

Continue Reading

TuesdayJul 07, 2020 12:40 pm

BioMedNewsBreaks – InvestorBrandNetwork Announces Launch of Technology-Driven Communications Platform – BioMedWire

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, today announced the launch of BioMedWire (“BMW”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. A laser-focused, technology-driven communications platform, BioMedWire is designed to provide the latest updates and information related to emerging market opportunities in the life sciences sector and beyond. “The life sciences sector has delivered incredible remedies and cures, saved and changed lives, and offered some of the greatest investment returns the markets have ever seen. The sector is constantly moving and evolving to meet…

Continue Reading